Prometheus raises $12 billion in capital for artificial engineers

Nonprofit Blood Cancer United acquires cancer drug, Lilly and Nvidia invest in Abridge, and more biotech news research NIH CMS Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout Prometheus raises $12 billion in capital for artificial engineers Nonprofit Blood Cancer United acquires cancer drug,…

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

AI continues to draw massive capital and new use cases in biopharma: Take Prometheus’ $12 billion raise to build “artificial general engineers,” or Abridge’s new partnerships with Eli Lilly and Nvidia, which aims in part to optimize the clinical trial recruitment process.

Plus, a nonprofit buys a shelved drug for a pediatric leukemia with plans to distribute it for free.

Continue to STAT+ to read the full story…